LNP

Advanced CAR-T and CAR-NK Engineering Solutions for Next-Generation Cell Therapy Research

 

 

Chimeric Antigen Receptor (CAR) technologies are transforming next-generation cell therapy research by enabling immune cells to recognize and eliminate tumor and other disease-associated cells. However, designing and validating CAR constructs can be complex and time-consuming during early research phases.

Through its partnership with ProMab, Tebubio provides access to a comprehensive toolbox for CAR-T and CAR-NK engineering, including ready-to-use cryopreserved CAR-T cells, over 100 off-the-shelf CAR constructs, non-viral mRNA-LNP immune-cell engineering technologies, and custom CAR development services.

CAR-Engineered T-Cells as Adaptive Immune Effectors

Chimeric Antigen Receptor T (CAR-T) cells are genetically engineered T lymphocytes designed to recognize tumor-associated antigens independently of major histocompatibility complex (MHC) presentation. Upon antigen engagement, CAR signaling triggers T-cell activation, cytotoxicity, cytokine secretion, proliferation, and long-term persistence, forming the basis of adaptive immune memory.

CAR-T Product Portfolio

Find the products???

Real-Time Functional Potency Assay for CAR-T Cells Targeting Solid and Hematological Cancers

Fig. 1: Functional cytotoxicity assay used in ProMab CAR-T development 

CAR-Engineered NK Cells as Innate Immunity Effectors

Chimeric Antigen Receptor NK (CAR-NK) cells are genetically engineered natural killer cells that combine CAR-mediated antigen specificity with endogenous NK-cell cytotoxic mechanisms in an MHC-independent manner. Upon target recognition, CAR-NK cells rapidly induce cytotoxic effector functions while retaining innate immune signaling pathways and a reduced propensity for long-term persistence.

CAR-NK Cells Generated with mRNA-LNPs Kill Tumor Target Cells In Vitro and In Vivo

Virus-Free, without Integration or Electroporation

 

Fig. 2 A-B: 78–95% CAR expression was achieved 16 hours post-transfection in CD19 and BCMA CAR-NK cell.
Fig. 2 C: Preserved NK phenotype: CD56⁺, CD16⁺, CD337⁺, CD3⁻

 

Fig 3: Efficient Target Cell Killing: Real-time cytotoxicity assays demonstrate that CAR-NK cells efficiently eliminate multiple myeloma cells (RPMI-8226 and MM1S) compared to unmodified NK cells.
Dose-Dependent Activity: Increasing CAR-NK effector-to-target ratios significantly enhance tumor cell killing.

Fig. 4: In Vivo Tumor Suppression: In a xenograft mouse model, CD19 CAR-NK cells significantly reduce tumor burden compared with PBS and NK cell controls.

mRNA Tools for Next-Gen Immunotherapy, Gene Editing & Cell Engineering

mRNA Category Application Key Examples
CAR mRNAs Engineering CAR-T/NK cells CD19, BCMA, HER2 – virus-free CAR constructs via mRNA-LNP
Bispecific Ab mRNAs Redirecting T cells to tumors EpCAM–CD3, HER2–CD3 – mRNA-encoded T cell engagers
Checkpoint scFv-Fc / mAbs Blocking immune inhibition PD-1 scFv-Fc, PD-L1 scFv-Fc; full IgGs like Nivolumab (anti-PD-1), Atezolizumab (anti-PD-L1)
Gene Editing / Antigen delivery CRISPR or vaccine studies Cas9-HA, COVID-19 Spike
Immune Modulators Activating or suppressing immune responses IL-4, IL-21, GM-CSF, PD-1, PD-L1 – natural regulators
Stem Cell Factors Reprogramming or iPSC induction Oct-4, SOX2 – pluripotency & lineage conversion
Fluorescent Reporters & mCherry mRNA-LNP Tracking expression visually eGFP, mCherry, Luciferase – for monitoring transfection
Empty LNPs Negative control LNPs without mRNA – for background signal validation

mRNA-LNP Applications Across Immune Cell Types

Infographic of lipid nanoparticle LNP applications for T-cells NK cells macrophages

Application of mRNA-LNP reagents across lymphoid, myeloid, and stem-cell–derived immune systems:

  • Primary T cells
  • NK cells
  • Macrophages
  • Dendritic cells
  • iPSCs and stem-cell–derived immune cells

What Sets ProMab’s CAR Engineering Tools Apart

  • Ready-to-use cryopreserved CAR-T cells for rapid functional studies
  • 100+ CAR constructs available (DNA, mRNA, LNP, or engineered cells)

mRNA-LNP delivery :

  • No cloning. No viral packaging. Fast, streamlined workflows
  • 78–99% transfection efficiency in primary T, NK, iPSC, and dendritic cells
  • Integrated functional assays, including real-time killing, binding, and cytokine analysis
  • Clinically validated technology, supported by 20+ patents and 4 clinical-stage programs (up to Phase II)

  • References


    Article content created by Tebubio using courtesy materials provided by ProMab.

Custom Project? Let’s Talk.

Tebubio is the exclusive European scientific interface of ProMab, providing direct access to expertise and tailored CRO support.